Inventiva (NASDAQ:IVA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Inventiva (NASDAQ:IVA) to a hold rating in a report issued on Saturday morning.

Several other analysts have also recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Inventiva in a report on Tuesday, September 30th. HC Wainwright boosted their price target on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Piper Sandler began coverage on Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Finally, Guggenheim upped their target price on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.14.

Inventiva Stock Performance

NASDAQ:IVA opened at $4.85 on Friday. The stock’s 50-day moving average is $5.28 and its 200-day moving average is $4.01. Inventiva has a 1-year low of $2.11 and a 1-year high of $6.55.

Hedge Funds Weigh In On Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,558 shares of the company’s stock after buying an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 as of its most recent SEC filing. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.